Solidago chilensis Meyen (Compositae) is a species native to South America (Brazil) popularly known as arnica. In Brazilian popular medicine, inflorescences and rhizomes of this plant have been used since the end of the 19th century to replace the exogenous and hepatotoxic Arnica montana L. in the treatment of edema and inflammatory pathologies. Although the anti‐inflammatory activity of S. chilensis is evidenced in the literature, there is a lack of studies with enriched fractions or compounds isolated from it. The objective of the current study was to characterize phytochemically and to evaluate the pharmacological action in vivo and in vitro of the crude extract and the different fractions (hexane, dichloromethane, acetal, butanolic, and aqueous) isolated from the inflorescence of S. chilensis. The inflorescence crude extract (ScIE) and fractions were administered by intraperitoneal route to mice at different doses. In an LPS‐induced pleurisy model, inhibition of leukocyte influx was observed for the ScIE and all fractions tested, as compared to controls. Dichloromethane (ScDicF), butanolic (ScButF), and aqueous (ScAquF) were selected for further analysis as they showed the best inhibitory effects in leukocyte migration and inflammatory cytokine and chemokine production: TNF‐α, CXCL1/KC, CXCL2/MIP‐2, and CCL11/eotaxin‐1. In LPS‐stimulated J774A.1 cell line, ScIE and the ScDicF exhibited an inhibitory effect on nitric oxide (NO) production and downmodulated the COX‐2 expression; ScAquF failed to modulate NO production and COX‐2 expression. In phytochemical analysis, HPLC‐UV‐DAD chromatograms of ScDicF and ScAquF showed the main peaks with UV spectrum characteristics of flavonoids; chlorogenic acid and isoquercetin were the most present phytochemicals identified in the ScAquF, and a high number of n‐alkanes was found in ScHexF. Our study was the first to address biological effects and correlate them to phytochemically characterized fractions from inflorescences of S. chilensis.
11 October 2024 in European Journal of Pharmacology
The consumption of green tea ( Camellia sinensis (L.) Kuntze) in the form of encapsulated dietary supplements has increased substantially in recent years; however, data supporting toxicological risk assessment of inorganic contaminants in these products remain limited. Unlike traditional tea infusions, encapsulated supplements deliver concentrated plant material in fixed daily doses, requiring exposure‐based rather than concentration‐based toxicological evaluation. In this study, arsenic (As), cadmium (Cd), and lead (Pb) were quantified in 11 batches of commercially available encapsulated green tea supplements from six brands marketed in Southeast Brazil. Elemental analysis was performed using graphite furnace atomic absorption spectrometry (GF AAS), and measured concentrations (mg·kg −1 ) were converted into estimated daily intake (EDI, μg/day) based on the maximum labeled intake. Toxicological relevance was primarily assessed using permitted daily exposure (PDE) limits established in United States Pharmacopeia (USP) Chapter , with complementary interpretation based on estimated weekly intake (EWI) and provisional tolerable weekly intake (PTWI) reference values. Estimated daily exposures to arsenic, conservatively assumed as inorganic arsenic, and cadmium remained below their respective PDE values in all analyzed batches. In contrast, lead exposure exceeded the USP PDE of 5 μg/day in two batches, revealing batch dependent noncompliance under an exposure‐based regulatory framework. These findings demonstrate that dietary supplements may act as concentrated sources of elemental exposure and highlight the importance of dose‐normalized assessment for accurate risk characterization. The integration of PDE with complementary exposure metrics strengthens the evaluation of toxicological risk and supports more robust, exposure‐based regulatory approaches for the safety assessment of botanical dietary supplements.